4.6 Article

Consequences of a Rare Complement Factor H Variant for Age-Related Macular Degeneration in the Amish

Journal

Publisher

ASSOC RESEARCH VISION OPHTHALMOLOGY INC
DOI: 10.1167/iovs.63.9.8

Keywords

age-related macular degeneration; complement factor H; rare variant; protein structure

Categories

Funding

  1. National Institutes of Health (NIH)
  2. postdoctoral NIH Visual Sciences Training Program [EY023164]
  3. CWRU Visual Sciences Training Program [T32EY007157-18]
  4. Clinical and Translational Science Collaborative (CTSC) of Cleveland - National Institutes of Health (NIH), National Center for Advancing Translational Science (NCATS), Clinical and Translational Science Award (CTSA) grant [T32 EY 7157-19]
  5. [TL1TR002549]

Ask authors/readers for more resources

This study investigates the functional effects of a genetic variant (P503A, rs570523689) in the complement factor H gene (CFH) that has been associated with age-related macular degeneration (AMD) risk. The researchers identified additional carriers of this variant and examined differences in AMD diagnosis and CFH expression levels between carriers and noncarriers. Although no significant differences were found, computational protein modeling suggested slight structural changes in CFH protein that may affect its binding or function. Further research is needed to confirm these findings.
PURPOSE. Genetic variants in the complement factor H gene (CFH) have been consistently implicated in age-related macular degeneration (AMD) risk. However, their functional effects are not fully characterized. We previously identified a rare, AMD-associated variant in CFH (P503A, rs570523689) in 19 Amish individuals, but its functional consequences were not investigated. METHODS. We performed genotyping for CFH P503A in 1326 Amish individuals to identify additional risk allele carriers. We examined differences for age at AMD diagnosis between carriers and noncarriers. In blood samples from risk allele carriers and noncarriers, we quantified (i) CFH RNA expression, (ii) CFH protein expression, and (iii) C -reactive protein (CRP) expression. Potential changes to the CFH protein structure were interrogated computationally with Phyre2 and Chimera software programs. RESULTS. We identified 39 additional carriers from Amish communities in Ohio and Indiana. On average, carriers were younger than noncarriers at AMD diagnosis, but this difference was not significant. CFH transcript and protein levels in blood samples from Amish carriers and noncarriers were also not significantly different. CRP levels were also comparable in plasma samples from carriers and noncarriers. Computational protein modeling showed slight changes in the CFH protein conformation that were predicted to alter interactions between the CFH 503 residue and other neighboring residues. CONCLUSIONS. In total, we have identified 58 risk allele carriers for CFH P503A in the Ohio and Indiana Amish. Although we did not detect significant differences in age at AMD diagnosis or expression levels of CFH in blood samples from carriers and noncarriers, we observed modest structural changes to the CFH protein through in silico modeling. Based on our functional and computational observations, we hypothesize that CFH P503A may affect CFH binding or function rather than expression, which would require additional research to confirm.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available